Endometriosis Treatment Market Size, Share, Opportunities, Revenue and Growth Rate Through 2030
Increasing investments in the endometriosis treatment market by key stakeholders and rising awareness among women are the major factors expected to drive market growth. The global endometriosis treatment market was valued at US$ 2.8 Bn in 2018, and is expected to exhibit a CAGR of around 3% over the forecast period (2019-2030).
Rising prevalence of endometriosis condition has fueled the demand for endometriosis treatment across the world. High focus on the introduction of therapeutically-advanced endometriosis treatment options are expected to propel the growth of the market over the forecast period. Leading industry players are significantly accelerating the development of scientific and clinical therapeutic agents and new product launches in the global endometriosis treatment market. This considerable push by industry players is expected to drive future market growth.
Key Takeaways of Endometriosis Treatment Market Study
- Based on drug, oral contraceptives contributed maximum value share to the global endometriosis treatment market in 2018, owing to high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
- High treatment efficacy and acceptance with low risk are expected to result in notable share of hormonal therapy in the treatment type.
- The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of value share to the endometriosis treatment market, owing to the high patient pool in hospitals and visiting retail pharmacies.
- Europe captured a notable revenue share of 37% in 2018, and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
- Increasing government expenditure for high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment market across this region.
Request Sample PDF Brochure:
Multiple New Indications – Imperative Strategy for Market Players
Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa (elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.
What else is in the report?
Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on drug (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Oral Contraceptives
- GnRH Analogues
- Hormonal Therapy
- Pain Management
- Hospital Pharmacies
- Retail Pharmacies
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa (MEA)
Ask for Customization:
Table of Content
- Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
- Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
- Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Drug Development Trends
- Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Endometriosis Epidemiology, By Key Region
4.3. Unmet Needs of Endometriosis Treatment
4.3.1. Potential Diagnostic Biomarkers for Endometriosis
184.108.40.206. Existing & Emerging Non-invasive Diagnostics Techniques
4.3.2. Disease Awareness and Educational Strategies for Medical Professionals
4.3.3. Drug Effectivity & Safety, By Drug
4.3.4. Marketed & Emerging Non-hormonal Therapies for Endometriosis
4.3.5. Disease Etiology and Pathophysiology
4.4. Research and Development Strategies
4.4.1. Reformulations and Label Expansion of Currently Marketed Drugs
4.4.2. Pipeline Assessment of GnRH Antagonists
4.4.3. Pipeline Assessment of Novel Non-hormonal Therapies
4.4.4. Key Strategies Followed By Manufacturers (Alliance, In-Licensing and Out-Licensing Strategies)
4.4.5. Strategy to Maximise Return on Investment (Drug Approvals for Secondary Indication)
4.5. Attributes/Factors Important in Clinical Trials
4.6. Clinical Trial History of Key Marketed Drugs
4.7. Attributes/Factors considered for Market Sizing of Historical Market Sizing & Opportunity Assessment of Pipeline Drugs
4.8. Pipeline Assessment/Clinical Benchmark Analysis
4.8.1. Marketed Drug/Pipeline Valuation Analysis
220.127.116.11. Therapeutic Advantages by Drug
18.104.22.168. New Drug Launches and Regulatory Approvals, 2019-2030
22.214.171.124. Opportunity Assessment in terms of Revenue, 2020-2025
126.96.36.199. Clinical Trials and Pipeline Overview
4.9. Regulatory Scenario
4.10. Reimbursement Scenario
4.11. Primary Verbatim, Key Opinion Leaders Opinion on Future Opportunities
Inquire Before Buying Research Report:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
For Sales Enquiries: email@example.com